A dose-finding study to address safety (and efficacy) of Vorinostat in Alzheimer‘s Disease

Background and aims

This project aims assess the safety, tolerability of Vorinostat in the elderly population and to obtain first exploratory data on the efficacy of Vorinostat in improving cognition and memory in patients with mild symptomatic forms of Alzheimer’s disease.

Vorinostat was approved by the FDA in 2006 for the treatment of refractory cutaneous T-cell lymphoma (CTCL). Vorinostat is not approved for the treatment of Alzheimer’s disease, and no results are available with regard to the tolerability in elderly patients. This study is based on animal experimental data showing an improvement of memory function after the administration of Vorinostat.

Course of the study

Safety and tolerability will be assessed by physical examinations, electrocardiograms (ECGs), laboratory tests, and vital signs. Experimental data on efficacy will be determined based on cognitive and functional scales. In addition study participants will be asked to undergo a magnetic resonance imaging.

A full set of information about the study can be downloaded here (in German only): Flyer Vorinostat_AD

Principle Investigator: Prof. Dr. Anja Schneider
Status: multi centric, ongoing, recruiting aktiv

Study Coordination / Project Management

Dr. Sandra Kuhs
 +49 228 43302-846
 +49 228 43302-812

Rebecca Sterl
 +49 228 43302-838
 +49 228 43302 812

Participating sites


Zentrum für Klinische Forschung
Local principle investigator:
Prof. Dr. Anja Schneider
+49 43302 849


Universitätsmedizin Göttingen
Gedächtnisambulanz, Klinik für Psychiatrie und Psychotherapie:
Local principle investigator:
Prof. Dr. Jens Wiltfang
+49 551 398 496
+49 551 396 6610


Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Inform yourself on our website cookie-free. However, we would be pleased if you would allow us to use statistical cookies. Your browser settings regarding cookies are currently as follows:
More information can be found in our Privacy policy.